Document is current

Article History

Accepted: 21 March 2023

First Online: 21 April 2023

Competing interests

: M.J.M. has received travel support from Pierre Fabre. E.LeR. has received grant/research support from Bristol Myers Squibb; and honoraria for lectures or advisory board participation from Adastra, Bayer, Janssen, Leo Pharma, Pierre Fabre and Seattle Genetics. A.S.B. has received research support from Daiichi Sankyo and Roche; honoraria for lectures, consultation or advisory board participation from Bristol Myers Squibb, Daiichi Sankyo, Merck and Roche; and travel support from AbbVie, Amgen and Roche. P.K.B. has consulted for Advice Connect Inspire, Angiochem, Axiom, Dantari, ElevateBio, Genentech/Roche, Lilly, MPM Capital, Pfizer, SK Life Sciences and Tesaro; has received institutional grant/research support (to Massachusetts General Hospital) from Bristol Myers Squibb, Lilly, Merck and Mirati; and has received honoraria from Genentech/Roche, Lilly, Merck and Pfizer (all outside the scope of this work). N.U.L. has received non-financial support from Seagen for manuscript preparation during the conduct of research studies; grants from AstraZeneca, Genentech, Merck, Olema Pharmaceuticals, Pfizer, Seagen and Zion Pharmaceuticals outside the submitted work; personal fees from Affinia Therapeutics, Aleta BioPharma, AstraZeneca, Daiichi Sankyo, Denali Therapeutics, Olema Pharmaceuticals, Pfizer, Prelude Therapeutics, Puma, Seagen and Voyager Therapeutics outside the submitted work; consulting fees from Affinia Therapeutics, Aleta BioTherapeutics, Artera, AstraZeneca, Daiichi Sankyo, Denali Therapeutics, Olema Oncology, Pfizer, Prelude Therapeutics, Seagen and Voyager Therapeutics; and royalties from UpToDate outside the submitted work. A.B.L. has received within the past 5 years travel, publication, other in-kind support, honoraria for consulting or advisory board participation and institutional research funding from Abbott and/or AbbVie, and in the past year has received travel, publication or other in-kind support from Chimerix, Karyopharm, Norwest Biotherapeutics, Pfizer, QED and VBI Vaccines; honoraria for consulting or advisory board participation from Affinia Therapeutics, Bioclinica (as an expert, blinded, independent reviewer of de-identified clinical data for a Bristol Myers Squibb-sponsored trial), Chimerix, Clinical Education Alliance, Leal Therapeutics, Novocure, Orbus and Sapience; and institutional research funding from AbbVie, Aeterna Zentaris, Bayer, Beigene, Bristol Myers Squibb, Cadmon, Chimerix, DelMar, Genentech/Roche, Kadmon, Karyopharm, Kazia, Keryx, Millennium, NextSource, Orbus, Pfizer, QED, Semus, Servier and VBI Vaccines. P.Y.W. has received honoraria for consulting or advisory board participation from AstraZeneca, Bayer, Black Diamond Therapeutics, Cellularity, Chimerix, Day One Biopharmaceuticals, Kazia, Merck, Mundipharma, Novartis, Novocure, Nuvation Bio, Prelude Therapeutics, Sapience Therapeutics, Servier, Tocagen, Vascular Biogenics and VBI Vaccines; and research funding from Agios, AstraZeneca, Bayer, Beigene, Celgene, Chimerix, Karyopharm Therapeutics, Kazia, MedicicNova, Merck, Novartis, Nuvation Bio, Oncoceutics, Puma Biotechnology, Vacular Biogenics and VBI Vaccines. M.W. has received research grants from Quercis and Versameb; and honoraria for lectures or advisory board participation or consulting from Bayer, Medac, Merck (EMD), Novartis, Orbus and Philogen. M.P. has received honoraria for lectures, consultation or advisory board participation from AbbVie, AstraZeneca, Bayer, BMJ Journals, Bristol Myers Squibb, CMC Contrast, Daiichi Sankyo, Gerson Lehrman Group, GlaxoSmithKline, Lilly, Medahead, MedMedia, Merck Sharp & Dohme, Mundipharma, Novartis, Roche, Sanofi and Tocagen; and institutional research support from AbbVie, Boehringer-Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Merck Sharp & Dohme, Novocure and Roche. R.B., J.C., H.K.G. and M.v.d.B. declare no competing interests.